Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.
Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.
Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.
Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.
Mazor Robotics and Medtronic will now be able to market and sell the Mazor X Surgical Assurance Platform in countries that recognize the CE Mark.
The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.
We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.
Medtronic (MDT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.
Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.
United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.
Medtronic is a pure-play medical device company. As a quick overview, Medtronic is split up into four segments: the Cardiac and Vascular Group (CVG), the Minimally Invasive Group (MITG), the Restorative Therapies Group (RTG), and the Diabetes Group (DG). For those who are unfamiliar, let’s first talk about diabetes and survey the available treatments.
Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.